T1	Participants 627 894	399 out of 457 patients recruited in this study were divided in a good or poor prognostic group depending on the presence of two or more poor prognostic factors, these were pain requiring treatment, >5 bone metastases, hydronephrosis, and alkaline phosphatase >2 ULN.
T2	Participants 1235 1275	patients with metastatic prostate cancer
